Global Human Growth Hormone Market By Product (Liquid and Powder), By Indication (Growth Hormone Deficiency, Prader-Willi Syndrome, Turner Syndrome, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The global human growth hormone market size is expected to be worth around USD 3.4 Billion by 2022 from USD 7.3 Billion in 2032, growing at a CAGR of 8.1% during the forecast period from 2022 to 2032.

Human growth hormone, also called somatotropin, is a peptide hormone that stimulates growth. Human growth hormone promotes cell regeneration and reproduction in individuals and other animals. It is, therefore, important in human enlargement. Growth hormone also encourages the production of IGF-1 and increases the concentration of free fatty acids.

Human growth hormone aids in the management of hormonal imbalance disorders and improves market development. Growth hormone deficiency in humans is initiated when the pituitary gland doesn’t manufacture sufficient focus of human growth hormone. Several genetic diseases, such as Turner syndrome and Parder-Willi syndrome, may similarly cause a growth hormone lack in humans, prominent to hindered puberty and smaller than average height.

Driving Factors

Increasing Incidence of Growth Disorders to Drive the Human Growth Hormone Market Growth

There has been a steady rise in public understanding regarding the usage of synthetic growth hormone therapy. Owing to the rise in diseases associated with growth hormone deficit, and the increase in usage of raging hormones, determinations are taken by the government and several private organizations to spread consciousness of growth hormone deficiency, and robust efficiency drives the market growth.

A strong product portfolio and wide R &D activities for the expansion of new growth hormone therapies are anticipated to be the significant factor propelling the market growth. Rising government initiatives are projected to significantly fuel market growth. Additionally, increasing awareness about synthetic growth hormone therapy in emerging countries drives market growth.

Restraining Factors

High-Cost of Synthetic Growth Hormone Hamper Market Growth

The high cost of growth hormone therapies and several side effects related to human growth hormone may hamper the market growth. Stringent rules and regulations for the usage of human growth hormone by athletes and sports specialists are anticipated to hinder the market growth. Economic restrictions faced by developing countries and several obstacles in the market decrease market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic is expected to influence the market. Patients with a lack of growth hormone secretion present a risk factor for COVID-19, which need attention that will aid in preventing the COVID-19 outbreak. Also, patients who are suffering from Prader-Willi syndrome also require attention that will benefit the prevention of the COVID-19 pandemic.

The COVID-19 outbreak has stressed and impacted the healthcare systems around the globe. The global lockdown situation has created difficulties for patients and healthcare providers.

By Product Analysis

Powder Segment to Witness Significant Growth

The global human growth hormone market is segmented into liquid and powder. The powder segment dominated the highest market revenue share of 56.5% in 2022. The most usual process in which growth hormones are provided is in powder form. This growth hormone is in a lyophilized powder form.

The lyophilized powder is then prepared into suspension with several concentrations in demand to produce growth hormone injectable doses. It helps to regulate composition, body fluids, muscle, and bone growth.

The liquid segment dominated during the historical period and is estimated to hold the second-largest market share. The great attention of human growth hormone preparation that contains glycine does not have crystallization and is suitable for human growth hormones.

By Indication Analysis

The Growth Hormone Deficiency Segment Dominates the Market Growth of the Human Growth Hormone Market

Based on Indication, the global human growth hormone market is classified into growth hormone deficiency, turner syndrome, Prader-Willi syndrome, and others. The growth hormone deficiency segment accounted for the maximum market revenue share of 35.6% in 2022.

This can be attributed to the rise in awareness related to the initial detection and treatment of growth hormone deficiency in individuals and the launching of innovative medications for the human growth hormone. It is an endocrine disease categorized by the less excretion of growth hormones.

The Turner syndrome segment is anticipated to witness the fastest growth rate during the forecast period. Owing to the rising initiatives by several public and private organizations to spread attention about the initial identification and treatment of Turner syndrome.

Furthermore, this Turner syndrome affects females.  Each year in February, non-profit administrations such as the Turner Syndrome Support Society and Turner Syndrome Foundation notice “Turner Syndrome Awareness Month” and undertake a global movement to increase consciousness of the disease. 

By Route of Administration Analysis

The Parenteral Segment Hold the Highest Market Revenue Share During the Forecast Period

Based on the route of administration, the global human growth hormone market is categorized into parenteral oral and. Among these, the parenteral segment dominated the highest market revenue share in 2022.

The fact is that when the hormone is injected by parenteral routes, it is mainly absorbed in the cells, which is essential for the patients. Human growth hormone is injected to treat deficiency. The oral segment is anticipated to grow at a CAGR of 5.8%.

By Distribution Channel Analysis

The Hospital Pharmacy Segment Dominated the Human Growth Hormone Market

Based on the distribution channel, the global human growth hormone market is divided into retail pharmacy, hospital pharmacy, and online pharmacy.  Among these, the hospital pharmacy segment registers the highest CAGR during the forecast period.

Recognized the inclination and comfort of accessibility of artificial human growth hormone in hospital pharmacies. The increasing awareness about growth hormone deficit among individuals and the treatment drives the segment’s growth.

The online pharmacy segment registers a CAGR of 6.4% in the human growth hormone market due to the high permeation of pharmacies in emerging countries. Further, the rising trend of online pharmacies in developing countries will propel segment growth in the upcoming years.

Key Market Segments

By Product

• Liquid
• Powder

By Indication

• Growth Hormone Deficiency
• Prader-Willi Syndrome
• Turner Syndrome
• Other Indications

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Growth Opportunity

Increasing Number of Novel Product Approvals

An increase in the approval of novel product approval and strategic collaboration among key players provides lucrative opportunities for the market. Additionally, a rise in the number of hospital pharmacies will offer significant opportunities for market growth.

Owing to the rising compliance for the treatments of growth hormone-related disorders and a big untapped market in emerging countries offer high revenue generation opportunities in the developed regions. Due to their wide populations, India and China are becoming key opportunity areas for the healthcare industry in the upcoming years.

Latest Trends

Increasing Trend of Online Pharmacies in Developing Regions is the Global Trends in the Market

The increasing number of online pharmacies in developed regions such as the US and Europe is the trend in the global human growth hormone market. An increase in the prevalence of growth hormone deficiency drives market growth. Human growth hormone is used for the treatment of several medical conditions, such as Turner syndrome, growth hormone deficiency, and chronic kidney disease. Synthetic human growth hormone is available in most counties without a doctor’s prescription.

Regional Analysis

North America Dominates the Global Human Growth Hormone Market During the Forecast Period

North America accounted for a significant human growth hormone market revenue share of 37.4%. Owing to the variations such as favorable reimbursement policies, established healthcare infrastructure, and expanding healthcare consciousness.

Further, rising access to inventive pharmaceuticals as a result of the presence of important firms in the region helps the US market. The increase in the geriatric population and the presence of various market giants dominated the North American market.

The Asia-Pacific market is anticipated to hold the maximum revenue share during the forecast period. Market players are focusing on obtaining a significant share in potential countries of the APAC, such as China and Japan, by obtaining adoption and introduction of new products.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America

• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The human growth hormone market is highly developed, with the presence of many international and domestic key players key operating in the market. This market player is experiencing strategic developments in order to remain competitive and obtain a significant market share. Various companies are focusing on developing long-acting human growth hormones.

The main companies are operating various strategies such as new product launches and collaborations. Some of the prominent key players in the human growth hormone market include Novartis AG, Merck KGaA, Pfizer Inc., Ferring B.V., Eli Lily and Company, and other key players.

Top Key Players

• Novartis AG
• Merck KGaA
• Pfizer Inc.
• Ferring B.V.
• Genetech Inc.
• Eli Lily and Company
• Novo Nordisk A/S
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Other Key Players

Recent Development

• February 2021-Pfizer Inc. and OPKO Health Inc. introduce that the European Medicines Agency has accepted Somatrogon for the cure of juvenile growth hormone deficiency patients.
• August 2021- Ascendis Pharma received Food and Drug Administration approval for their SKYTROFA injectable in August. These products will be released in the whole market, approving the corporation to make major revenue.

Report Scope